On May 16th, 2021, "Tumor Molecular Diagnosis Frontier Research and Clinical Test Application Salon" was successfully held in Nanjing, hosted by Nanjing Medical Association Laboratory Specialty Branch and Nanjing Medical Association Laboratory Specialty Branch Youth Committee, and organized by Oncor Life Sciences (Suzhou) Co. A number of test experts and nearly 100 test colleagues from Jiangsu Provincial People's Hospital, Nanjing Gulou Hospital, Eastern Theater General Hospital, The Second Affiliated Hospital of Nanjing Medical University, The First Hospital of Nanjing, Zhongda Hospital, Nanjing Maternity and Child Health Center, and other medical institutions participated in this event.

　　Figure / Salon activities

　　Photo / Prof. Shen Han, Executive Deputy Director of Laboratory Department, Nanjing Gulou Hospital

　　At 14:00 pm, Director Shen Han, the host of the salon, announced the official start of the academic program.

　　Photo / Prof. Pan Shiyang, Director of the Department of Laboratory Medicine, Jiangsu Provincial People's Hospital

　　Professor Pan Shiyang, Director of the Department of Laboratory Medicine of Jiangsu Provincial People's Hospital, made a speech at the beginning of the meeting, congratulating on the successful convening of the academic salon, affirming the rapid development of frontier research on tumor molecular diagnosis in China, and expressing great hope for the early realization of the full clinical application of genetic testing technology.

　　Keynote Speech

　　Photo / Prof. Wang Shukui, Deputy Secretary of Nanjing Hospital, Nanjing Medical University

　　During the keynote speech stage, Prof. Wang Shukui, Deputy Secretary of Nanjing First Hospital, delivered a keynote speech on "Carrying out exosome detection-assisting tumor liquid biopsy". The speech centered on the definition, characteristics, extraction methods, application value and cases of exosomes, and elaborated the importance of exosomes in tumor detection. During the speech, he listed three major application scenarios based on exosomes: biomarkers, drug carriers and tumor therapy, showing the wide prospects of exosome detection in clinical testing applications.

　　Photo / Dr. Hong Yan, Deputy Director, Center for Laboratory Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

　　In the keynote speech "Research on non-invasive molecular diagnosis of kidney cancer based on urinary free DNA", Dr. Hong Yan, Deputy Director of the Center for Laboratory Medicine, The Second Affiliated Hospital of Nanjing Medical University, systematically elaborated on the clinical significance of liquid biopsy in kidney cancer diagnosis, starting from the epidemiological characteristics of renal cancer, existing diagnostic techniques and limitations, and reported on the multi-center clinical trials based on this research. Based on this study, a multi-center clinical trial was conducted.

　　Chair

　　Photo/Professor Wang Junjun, Director of the Department of Laboratory Medicine, Eastern Theater General Hospital, presided over the review.

　　Prof. Wang Qianghu, Director of Department of Bioinformatics, Nanjing Medical University, China

　　Prof. Qianghu Wang, Director of the Department of Bioinformatics, Nanjing Medical University, gave a lecture on "Research on tumor metastatic potential marker clusters based on single-cell sequencing", focusing on the related research results in metastatic pancreatic cancer. It was found that a portion of metastasis-dominant cell subpopulations lead to tumor metastasis, and his team has identified the molecular features and the timing of metastasis occurrence of such cell subpopulations, and experimentally verified the intervention of metastasis-dominant subpopulations.

　　At the end of the report, Prof. Wang said, "Basic research is only meaningful if it is converted into services for clinical use and benefits patients." We hope that frontline clinical experts and testing colleagues will be able to give us advice and work together to help the translation of research results!

　　Moderator

　　Prof. Li Li, Deputy Director of Department of Laboratory Medicine, Zhongda Hospital, Southeast University, commented on the picture.

　　Photo / Dr. Lin Jiahui, General Manager of Suzhou Guokejunhao Biotechnology Co.

　　Dr. Jiahui Lin, General Manager of Suzhou Guokejunhao Biotechnology Co., Ltd. addressed the topic "Research on the application of microfluidic technology in clinical testing" and introduced the chip, disk and droplet microfluidic technology and the related representative companies and products, and explained in detail the application of microfluidic technology in different clinical fields.

　　Host

　　Photo/Chen Yajun, Director of Laboratory Department, Nanjing Maternal and Child Health Hospital, presided over the review.

　　Photo / Dr. Zhao Hui, CEO of ONC Life Sciences

　　At the end of the Salon, Dr. Zhao Hui, CEO of ONC Life Sciences, gave an in-depth academic report on DNA methylation biomarkers and detection technology. He said, through the in-depth study of the biological characteristics of DNA methylation, it has been proved that DNA methylation is the best marker for early screening of tumors, and DNA methylation is the third dimension of the biological genome, which makes the book of genome more complicated and fascinating.

　　He then analyzed the advantages and disadvantages of the existing tumor molecular diagnostic technologies, and highlighted the MeMore methylation ultrasensitive coupling technology independently developed by ONC.

　　Figure / Advantages of MeMore technology

　　MeMore technology is developed for detecting the methylation status of trace blood free DNA, which has the advantages of low cost, high throughput, high precision, multiple markers, good flexibility and short time, etc. NGS technology is more suitable for exploring the unknown field, while MeMore technology is more suitable for the industrialization of pan-cancer early screening technology.

　　Chair

　　Figure / Prof. Qianghu Wang, Dean of Bioinformatics Department, Nanjing Medical University, Nanjing, China

　　Photo / Group photo of experts and youth committee members

　　China is a large cancer country with tens of millions of families suffering from cancer, the incidence rate is increasing year by year, and the mortality rate remains high. There is a great demand for early cancer diagnosis, but there are still many technical problems on how to develop products that are easy to use and affordable to the general public in order to meet the huge social demand.

　　This academic conference not only hopes to promote the scientific research and application development of tumor molecular diagnosis through the collision of experts, scholars and enterprises, but also hopes that all walks of life can pay more attention to and support early cancer screening, and jointly promote the continuous improvement of the level of early diagnosis of tumors.